GSA Capital Partners’s Fulcrum Therapeutics FULC Stock Holding History

GSA Capital Partners’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$527K	Buy	143,911 +7,247	+5%	+$44.1K	0.03%	969
2026 Q1	$1.05M	Buy	136,664 +36,955	+37%	+$343K	0.07%	473
2025 Q4	$1.13M	Sell	99,709 -16,359	-14%	-$166K	0.1%	297
2025 Q3	$1.07M	Buy	116,068 +83,505	+256%	+$604K	0.09%	360
2025 Q2	$224K	Buy	+32,563	New	+$174K	0.02%	1442
2024 Q4	–	Sell	-17,142	Closed	-$61K	–	1746
2024 Q3	$61K	Sell	17,142 -118,079	-87%	-$876K	﹤0.01%	1513
2024 Q2	$838K	Buy	135,221 +120,059	+792%	+$909K	0.06%	623
2024 Q1	$143K	Buy	+15,162	New	+$135K	0.01%	1454
2022 Q4	–	Sell	-17,879	Closed	-$145K	–	1613
2022 Q3	$145K	Sell	17,879 -4,943	-22%	-$35.4K	0.02%	1303
2022 Q2	$112K	Buy	+22,822	New	+$223K	0.02%	1203

Other funds holding FULC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

GSA Capital Partners's FULC Position: Q2 2026 in Review

GSA Capital Partners increased its Fulcrum Therapeutics (FULC) stake by 5.3% in Q2 2026, buying an estimated $44.1K and bringing the position to 143,911 shares worth $527K. The position accounts for 0.03% of the portfolio, ranked #969.

GSA Capital Partners first reported a position in FULC in Q2 2022 and has held it in 10 quarters since. The position peaked at $1.13M in Q4 2025. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

GSA Capital Partners held 143,911 shares of Fulcrum Therapeutics worth $527K as of Q2 2026.
GSA Capital Partners bought 7,247 Fulcrum Therapeutics shares in Q2 2026, an estimated $44.1K.
Fulcrum Therapeutics made up 0.03% of GSA Capital Partners's portfolio in Q2 2026, its #969 holding.
GSA Capital Partners first reported a position in Fulcrum Therapeutics in Q2 2022 and has held it in 10 quarters since.
GSA Capital Partners's Fulcrum Therapeutics position peaked at $1.13M in Q4 2025.
154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.